Skip to main content

Advertisement

SpringerLink
Log in

Botulinumtoxin Injection Versus Augmentation Cystoplasty for Neurogenic Bladder: Where Do We Stand?

  • Review
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Patients with neurogenic bladder often present with overactive, low capacity, and poorly compliant bladders with discoordination of their internal and external urethral sphincters. As a result of poor compliance, high detrusor pressures can cause reflux into the upper tracts. This constellation of findings can also cause bothersome lower urinary tract symptoms. There are various modes of management for patients with neurogenic bladder ranging from conservative methods to major reconstructive surgery in efforts to prevent upper tract deterioration and to treat voiding dysfunction. This paper aims to review the current practices in treatment decision making when offering botulinumtoxin A versus augmentation cystoplasty for management of neurogenic detrusor overactivity.

Recent Findings

A comprehensive review was performed using PubMed and Cochrane Library from January of 2018 to April of 2023. As treatment for refractory neurogenic detrusor overactivity advances, intravesical BTX-A and augmentation cystoplasty are effective options for management, both independently and when used in combination.

Summary

From more recent literature, the approach in choosing which option is more clinically effective in terms of continence rates, improvement in urodynamic parameters, and patient satisfaction is progressing towards being more patient-centered rather than following an algorithm that progresses from least invasive to most invasive management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

Not applicable

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. McGuire E. Urodynamics of the neurogenic bladder. Urol Clin North Am. 2010;37(4):507–16.

    Article  PubMed  Google Scholar 

  2. Cheng PJ, Myers JB. Augmentation cystoplasty in the patient with neurogenic bladder. World J Urol. 2020;38(12):3035–46. A metanalysis looking at the indications and outcomes of augmentation cystoplasty in patients with neurogenic bladder.

    Article  PubMed  Google Scholar 

  3. Shreck E, Giola K, Lucioni A. Indications for augmentation cystoplasty in the year of onabotulinumtoxin A. Curr Urol Rep. 2016;17(27)

  4. Schulte-Baukloh H, et al. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology. 2002;59(3):325–7.

    Article  CAS  PubMed  Google Scholar 

  5. Chancellor M, Smith C. Use of botulinum toxin in the genitourinary system. Handb Exp Pharmacol. 2021;263:171–84.

    Article  CAS  PubMed  Google Scholar 

  6. Welk B, Richardson K, Panicket J. The cognitive of anticholinergics for patients with overactive bladder. Nat RevUrol. 2021;18:686–700.

    CAS  Google Scholar 

  7. Ginsberg D, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urology. 2012;187(6):2131–9.

    Article  CAS  Google Scholar 

  8. Cruz F, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Euro Urol. 2011;60(4):742–50.

    Article  CAS  Google Scholar 

  9. Apostolidis A, Papeafstathiou E, Gatsos S, G. Intravesical botox for overactive bladder: how to minimize complications and manage failures. Curr Drug Targets. 2020;21(15):1527–2536.

    Article  CAS  PubMed  Google Scholar 

  10. Biers A, Venn S, Greenwell T. The past, present and future of augmentation cystoplasty. BJU International. 2012;109(9):1290–3.

    Article  Google Scholar 

  11. Trojan K, et al. Improvement of bladder function after bladder augmentation surgery: a report of 2 years of clinical experience. Pediatr Surg Int. 2022;38:41–948. A retrospective study looking at the long-term effects and quality of life after bladder augmentation in patients with spina bifida.

    Article  Google Scholar 

  12. Stein R, Schroider A, Thuroff J. Bladder augmentation and urinary diversion in patients with neurogenic bladder: non-surgical considerations. J Pediatr Urol. 2012;8(2):145–52.

    Article  PubMed  Google Scholar 

  13. Myeres J, et al. The effects of augmentation cystoplasty and botulinum toxin injection on patient-reported bladder function and quality of life among individuals with spinal cord injury performing clear intermittent catheterization. Neurourol Urodynamics. 2019;38(1):285–94.

    Article  Google Scholar 

  14. Chieh Lin C, Chorng Kuo C. Video-urodynamic characteristics and predictors of switching from botulinum neurotoxin a injection to augmentation enterocystoplasty in spinal cord injury patients. Toxins. 2022;14(1):47. A comparison of urodynamics parameters before and after receiving botox and augmentation cystoplasty in spinal cord injury patients.

    Article  Google Scholar 

  15. Toia B, et al. The efficacy of onabotulinumtoxinA in patients with previously failed augmentation cystoplasty: cohort series and literature review. Neurourol Urodyn. 2020;39(6):1831–6.

    Article  CAS  PubMed  Google Scholar 

  16. Michel F, et al. Botulinum toxin type a injection after failure of augmentation enterocystoplasty performed for neurogenic detrusor overactivity: preliminary results of a salvage strategy. The ENTEROTOX study. Urology. 2019;129:43–7.

    Article  PubMed  Google Scholar 

  17. Padmanabhan P, et al. Five-year cost analysis of intradetrusor injection of botulinum toxin type and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urology. 2010;29:51–7.

    Article  Google Scholar 

  18. Kim S, et al. Cost comparison of intradetrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children. J Pediatr Urol. 2022;18(3):314–219.

    Article  PubMed  Google Scholar 

  19. Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. J Urolo. 2021;206:1106. The current guidelines on follow up management for neurogenic lower urinary tract dysfunction.

    Article  Google Scholar 

  20. Fendereski K, et al. Variation in provider practice patterns and the perceived need for a shared decision-making tool for neurogenic lower urinary tract dysfunction. Urology. 2023;174:185–90. A study looking at provider practice patterns when management neurogenic lower urinary tract dysfunction.

    Article  PubMed  Google Scholar 

  21. Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: diagnosis and evaluation. J Urol. 2021;206:1097.

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was received for this article.

Author information

Authors and Affiliations

  1. Department of Urology, Medical University of South Carolina, Charleston, USA

    Tara Sweeney, Kasparas Zilinskas & Lindsey Cox

Authors
  1. Tara Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kasparas Zilinskas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lindsey Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Kasparas Zilinskas performed a literature review needed to construct the review paper. Tara Sweeney wrote the main manuscript text. Lindsey Cox provided edits and suggestions to improve the main manuscript text. All authors reviewed the manuscript.

Corresponding author

Correspondence to Tara Sweeney.

Ethics declarations

Ethical Approval

Not applicable.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sweeney, T., Zilinskas, K. & Cox, L. Botulinumtoxin Injection Versus Augmentation Cystoplasty for Neurogenic Bladder: Where Do We Stand?. Curr Bladder Dysfunct Rep 18, 299–303 (2023). https://doi.org/10.1007/s11884-023-00719-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-023-00719-1

Keywords

Search

Navigation